113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster II

8-Oxoguanine DNA Glycosylase 1 Recruits Transcription Factor STAT1 to Promote the Inflammatory Responses in Sickle Cell Disease

Acquired Mutations in the Mitochondrial Genome As Prognostic Markers in Sickle Cell Disease

Alterations in the Immune Phenotype of Adaptive Immune Cells in Sickle Cell Disease: A Conventional and Computational Flow Cytometry Analysis

Blockade of Angiotensin II Signaling Ameliorates Cardiac Fibrosis and Improves Diastolic Dysfunction in Mice with Sickle Cell Anemia

Bruton Tyrosine Kinase Inhibitor Rilzabrutinib Reduces Vaso-Occlusion and Markers of Inflammation and Adhesion in Transgenic Mice with Sickle Cell Disease

Concurrent GBT1118 & Losartan Treatment Improves Sickle Cell Nephropathy

Defining Mechanistic Responses to Different Vaso-Occlusive Triggers in Sickle Cell Disease: A Step Towards Personalized VOC Reversal Strategies

In Vivo Sickle Cell Blood Rheology in Humans with Ventral Tongue Microscopy

Inhibition of the Complement Alternative Pathway Attenuates Hemolysis and Preserves Renal Function in a Mouse Model of Sickle Cell Disease

Long-Term Therapy with GBT021601 and Moderate Chronic Transfusion Therapy Prevent the Development of Hyperalgesia

Mitapivat-Induced Improvements in RBC Deformability and Membrane Integrity in Patients with Sickle Cell Disease Are Sustained during Extended Therapy

Pharmacological Evaluation of a First-in-Class Hemoglobin Elevating Agent (HbEA) AND017 in Townes SCD Mouse Model